Skip to search boxSkip to navigationSkip to main content

Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation [3]

  • Jan Volavka(corresponding author)
    ,
  • Karen A. Nolan
    ,
  • Linda Kline
    ,
  • Pal Czobor
    ,
  • Leslie Citrome
    ,
  • Brian Sheitman
*Corresponding author for this work
  • New York State Office of Mental Health
    ,
  • Dorothea Dix Hospital
    ,
  • North Carolina Department of Health and Human Services
    ,
  • University of North Carolina at Chapel Hill
Scholary Output:
Contribution to journal
Letter
 Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Publication Information

Output type

Scholary Output:
Contribution to journal
Letter
 Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 127-129 (3 pages)

Journal (Volume, Issue Number)

Schizophrenia Research (Volume 76, Issue 1)

Publication milestones

  • Published - 07/01/2005

Publication status

Published - 07/01/2005

ISSN

0920-9964

Publication IDs

  • Scopus: 20444450451
  • PubMed: 15927808

Access to documents

Publication metrics

Metrics

Scopus
citations
8, opens in new tab
SciVal
FWCI
0.85
SciVal
Author count
9
SciVal
citations
7
SciVal
Paper percentile
55
Fractional count
1
Fractional count
0.11
Fractional count
8
Fractional count
0.89
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
9
Captures
37

Funding Details

NIMH grant (R10 MH53550) provided the principal support for this project. Additional support was provided by the UNC-Mental Health and Neuroscience Clinical Research Center (MH MH33127) and the Foundation of Hope, Raleigh North Carolina. We thank Janssen Pharmaceutica Research Foundation, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, and Merck and Co. for their generous gifts of medications. Eli Lilly and Company contributed supplemental funding that covered approximately 18% of the total cost of the study. However, overall experimental design, data acquisition, statistical analyses, and interpretation of the results were implemented without any input from any of the pharmaceutical companies.
FundersFunding numbers
UNC-Mental Health and Neuroscience Clinical Research Center
MH MH33127
NIMH
P50MH033127